business
Psychedelic Drugmaker Definium Surges on Depression Drug Success
Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.
Read full story on Bloomberg Markets → More top storiesAlso covered by
DW English
High-functioning depression: When success masks suffering
Yahoo Finance
This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.
Investing.com
Definium to present phase 3 depression trial results Monday
STAT News
STAT+: Definium LSD therapy helped patients with major depression in late-stage trial
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop